Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02398240
Title Brentuximab for Newly Diagnosed Hodgkin Disease
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mitchell Cairo
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Doxorubicin + Rituximab + Vincristine Sulfate

Brentuximab vedotin + Doxorubicin + Vincristine Sulfate

Age Groups: child | adult
Covered Countries USA


No variant requirements are available.